Chat real-time with other investors about this CVTX news release,
by clicking this link: http://www.stockwire.com/CVTX
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=CVTX
(NasdaqGM:CVTX) Current Price (8.98) Sept. 27 -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) announced today that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking an expansion to the approved product labeling for Ranexa (ranolazine extended-release tablets). CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
----------------------------------------------------------
Chat real-time with other investors about this SPKL news release,
by clicking this link: http://www.stockwire.com/SPKL
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=SPKL
Spicy Pickle (OTC BB:SPKL) Current Price (0.95) Sep 27, 2007 -- Spicy Pickle fast casual restaurants (OTC BB:SPKL.OB - News) today announced it has signed its first franchisee in the state of Florida.A new franchisee with restaurant experience in another concept has entered into a franchise agreement to open the first Spicy Pickle Restaurant in the Ocala/Gainesville region of central Florida. Founded in 1999, Spicy Pickle Franchising, Inc. (OTC BB:SPKL.OB - News) serves high quality meats and fine artisan breads, baked fresh daily, along with a wide choice of eight different cheeses, twenty-two different toppings, and fourteen proprietary spreads to create healthy and delicious panini and sub sandwiches with flavors from around the world. As a leading ''fast-casual'' concept, Spicy Pickle offers menu items that are far beyond traditional fast food -- but without the price point of casual dining. The hallmark of a Spicy Pickle restaurant is quality, service and an enjoyable atmosphere. The company is headquartered in Denver, Colorado, with franchised locations now open across nine states and many more in development nationwide. For more about Spicy Pickle, including franchise information and inquiries, visit http://www.spicypickle.com.
----------------------------------------------------------
Chat real-time with other investors about this EBS news release,
by clicking this link: http://www.stockwire.com/EBS
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=EBS
(NYSE:EBS) Current Price (8.94) Sept 27--Emergent BioSolutions Inc. (NYSE:EBS - News) announced today that it has received a development contract, valued at up to $9.5 million, in support of non-clinical and clinical studies of the company's anthrax therapeutic, or AIG, product candidate. This product candidate is an immune globulin being developed as an intravenous therapeutic for treatment of patients who present with symptoms of anthrax disease following exposure to anthrax. Emergent BioSolutions, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the development, manufacture, and commercialization of immunobiotics. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that assist the body?s immune system to prevent diseases. It has two segments, Biodefense and Commercial. The Biodefense segment develops and commercializes immunobiotics for use against biological agents, which are weapons of bioterrorism. This segment?s primary product includes BioThrax, a vaccine for the prevention of anthrax infection. Its other products, which are in preclinical stage comprise Anthrax Immune Globulin, for post-exposure treatment of anthrax infection; Recombinant Bivalent Botulinum Vaccine, a prophylaxis for botulinum; and Botulinum Immune Globulin for post-exposure treatment of botulinum intoxication. The Commercial segment develops immunobiotics for use against infectious diseases with unmet or underserved medical needs. This segment?s product portfolio consists of Typhoid Vaccine, a single-dose drinkable vaccine in phase II clinical trial; Hepatitis B Therapeutic Vaccine, for treating chronic carriers of hepatitis B infection, which has completed phase I clinical trial; Group B Streptococcus Vaccine in phase I clinical trial; Meningitis B Vaccine, a recombinant protein sub-unit vaccine for babies, children, and adolescents that has completed phase I clinical trial; and Chlamydia Vaccine, for the prevention of chlamydia trachomatis in preclinical stage. Emergent BioSolutions serves primarily the department of defense and the health and human services. It operates in the United States, the United Kingdom, Germany, and Singapore. The company, formerly known as BioPort Corporation, was founded in 1998 and is based in Rockville, Maryland.
----------------------------------------------------------
Chat real-time with other investors about this DMSP news release,
by clicking this link: http://www.stockwire.com/DMSP
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=DMSP
(OTC BB:DMSP) Current Price (0.52) Sept 27--DIRT Motor Sports, Inc. d/b/a World Racing Group (OTCBB: DMSP - News) today announced the completion of the sale and issuance of $12 million of its 12.5% Senior Secured Notes maturing March 15, 2010 (the "Notes"). The proceeds from the financing will be used to retire certain short term notes issued in 2007, to repay certain debt outstanding issued in connection with the Company's speedway acquisitions, to repay debt incurred in the acquisition of the DIRT Northeast operation and to meet the Company's working capital needs in 2008. Based in Concord, N.C., World Racing Group (WRG) is a national sanctioning body, real-estate operator, and sports entertainment company serving the dirt racing industry. WRG sanctions sprint car racing under the World of Outlaws banner, late model racing under the World of Outlaws Late Model Series(SM), big block modified racing under the Advance Auto Parts Super DIRTcar Series(TM) banner and sanctions more than 4,000-races a year under the DIRTcar(TM) Racing banner. WRG races can be heard online at DIRTVision.com . In addition, WRG owns and operates seven speedways.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
